Summary The sulphydryl compound WR 2721 has been combined with a range of cytotoxic drugs in the mouse and the effects upon tumours and normal tissues determined. In the acute lethality (LD50130) assay, mean protection,factors produced by WR 2721 (200 or 400mgkg-') were generally less than 1.3 for cyclophosphamide (CTX), CCNU and chlorambucil (CHL) but a protection factor of 1.7 was obtained for cisplatinum (cis-P) in combination with 400mgkg-1 of WR 2721. No protection against the depression of peripheral white cell count seen at 3 days after CTX, CCNU or cis-P was obtained with either 200 or 400mgkg-' of WR 2721. Significant protection of the RIF-1 sarcoma by WR 2721 against CTX and cis-P induced growth delay was seen. In the KHT sarcoma, WR 2721 produced small reductions in the growth delay caused by CCNU, melphalan and CHL but these were not statistically significant. These data show less differential normal tissue protection by WR 2721 than do a number of reports in the literature.
The sulphydryl compound, WR 2721, has been developed as a selective protector of normal tissues against ionising radiation (Yuhas, 1980a) . More recently a number of papers have appeared which indicate that this compound is also able to selectively protect normal tissues in the mouse or rat against a number of cytotoxic drugs whilst having little or no effect upon the anti-tumour efficacy of these agents (Yuhas, 1979; Yuhas & Culo, 1980; Yuhas et al., 1980; Wasserman et al., 1981) . In our own study of cyclophosphamide (CTX) in combination with WR 2721, however, we found significant protection of two mouse tumours against CTX, whilst seeing less protection of normal tissues than reported by others (Twentyman, 1981) . In this paper, we report the results of a much larger series of experiments in which protection by WR 2721 against the effects of a range of cytotoxic drugs has been studied in both tumour and normal tissues of the mouse.
Materials and methods
Mice and tumours The mice used in these studies were inbred C3H/He supplied by OLAC. Females were used in most experiments, but males were used occasionally. Mice entered experiments at age 12-16 weeks and weighed 20-28 g.
Tumours used were the KHT and RIF-1 sarcomas, both of which originated in C3H/Km mice at Stanford University, California, and which have been previously described (Kallman et al., 1967; Twentyman, et al., 1980) . The methods used for tumour cell inoculation into the gastrocnemius 0007-0920/83/010057-07 $01.00 muscle of the hind limb and subsequent measurement of tumour growth, including conversion of leg measurement to tumour weight, have also been described (Twentyman et al., 1979) . The endpoint of growth delay was calculated from the geometric means of the times taken for individual tumours to reach 4 x the initial groupmean treatment volume. Tumours were treated in the size range 300-600mm3.
Nine to 12 mice were used in each treatment group.
White-cell counts Blood samples were taken from unanaesthetized mice by cutting a few mm from the end of the tail with a scalpel. A capillary pipette was then used to draw up 0.015ml of blood, which was diluted in 20 ml of "Isoton" (Coulter Electronics Ltd). Six drops of "Zapoglobin" were added to lyse the red cells, and counts were made on an electronic particle counter (Coulter Electronics-Model ZBI).
Drugs
WR 2721 (S,2-(3-aminopropylamlno)ethyl-phosphorothioc acid) was kindly supplied by the Drug Development Branch of the U.S. National Cancer Institute. Most Figure 2 Growth delay in the RIF-1 tumour with increasing dose of cis-P. * cis-P alone; 0 WR 2721 (400mgkg -) at 30min before cis-P.
the 7 experiments in which a direct comparison was possible, the groups receiving WR 2721 showed a smaller growth delay in 6 cases and the delays were identical in the seventh.
Discussion
The original data on the action of WR 2721 as a differential radioprotector of normal tissues (summarised by Yuhas, 1980a) showed two notable features. Firstly, the protection of a variety of different normal tissues in the mouse and in the rat could be obtained, with protection factors frequently in excess of 2.0 (neural tissue, however, being a notable exception). Secondly, with only a rare exception, no protection of tumours was found.
More recently, however, a number of papers have appeared which report significant radioprotection of a number of different murine solid tumours (Rojas et al., 1982; Clement & Johnson, 1982) and of micrometastases in the lungs of mice (Milas et al., 1982) .
This same course of events has been followed with regard to data on the ability of WR 2721 to protect normal tissues selectively from the effects of cytotoxic drugs. Reports of protection of normal tissues against nitrogen mustard (Yuhas, 1979) , cis-P (Yuhas & Culo, 1980) and CTX were all accompanied by findings of a lack of protection of tumours. Using the bone marrow CFUs assay in LAF1 mice, Wasserman et al., (1981) examined the ability of WR 2721 to protect against nitrogen mustard, CTX, BCNU, cis-P and 5-fluorouracil and obtained protection factors in the range 1.5 to 4.6. In a parallel study of the growth delay in EMT6 tumours little or no protection was seen (although it is not possible to estimate protection factors from the data). More recently, however, our own studies with CTX (Twentyman, 1981) and those of Clement & Johnson (1982) with MEL and CTX have shown significant protection. It must therefore be recognised that differential radio-and chemo-protection by WR 2721 are by no means absolute and that detailed studies of therapeutic ratios using a variety of normal tissue endpoints are required.
The dose of WR 2721 used and its time of administration with respect to radiation or cytotoxic drugs are important parameters to be considered in any study of interactions. In most radiation studies a time of 15-30min has been chosen as this allows peak levels of drug to be attained in most normal tissues whilst allowing little time for the slower absorption into tumours (Yuhas, 1980b) . A similar rationale has been used in chemoprotection experiments (Yuhas, 1979; Yuhas & Culo, 1980; Yuhas et al., 1980; Twentyman, 1981) . A potential artefact of drug interaction in the bloodstream has, however, been pointed out when very short times (5-15min for nitrogen mustard) are used (Yuhas, 1979) . Doses of WR 2721 used have generally been in the range of 200-600mgkg-1. In studies of radiation-induced haemopoietic death in 4 strains of mice, Yuhas (1980a) found that a protection factor of 2.0 was achieved at a WR 2721 dose of 200mgkg-1, compared with a value of 2.7 in the dose range 400-600mgkg-. For radiation damage to the mouse jejunum, a plateau of protection was achieved at a WR 2721 dose of 200mgkg-t, although further protection was seen in the mouse testis by increasing the dose from 300-500mgkg-1 (Milas et al., 1982) . Chemoprotection against nitrogen mustard (30-day survival) gave a protection factor of 1.5 for 200mgkg1 of WR 2721 compared with 1.9-2.0 at 400 mgkg 1, subsequently falling back to 1.5 at 500mgkg-' (Yuhas, 1979) .
Protection against the renal toxicity of cis-P in the mouse (as measured by day-5 elevation of blood urea nitrogen) was by factors of 1.2 and 1.5 at WR 2721 doses of 100 and 200mgkg-' respectively . In summary, therefore, although increases in protection factors are sometimes seen above a dose of 200 mg kg-1 of WR 2721, the major component of protection is usually seen at this dose level with typical protection factors of around 1.5. The data presented in this paper are, therefore, somewhat at variance with other reports on differential chemoprotection. In our earlier paper (Twentyman, 1981) Using depression of peripheral white cell count at Day 3 after drug treatment, however, we found no protection against CTX, CCNU, or cis-P at either 200 or 400mgkg-' of WR 2721. This result, in particular, is in marked contrast with data of Wasserman et al., (1981) where protection factors for mouse bone marrow CFUs of 2.4 and 3.2 were obtained for CTX and cis-P respectively (together with values of 4.6 and 1.5 for nitrogen mustard and BCNU). Clearly there are considerable differences in the target cell populations for the two assays. The 3-day nadir of white cell count is likely to reflect the effect of the drugs mainly upon the proliferating committed precursors of the white cell series with the subsequent recovery rate being determined by the earlier precursors (including CFUs). Although most progenitors of the granulocyte series are located in the bone marrow, lymphoid precursors are more widely distributed. As around 70% of peripheral white cells in the mouse are lymphocytes, drug effects in sites other than the marrow will be very important in determining the Day 3 peripheral count. Site-dependent differences in drug levels or in the degree of interaction between WR 2721 and the various cytotoxic drugs may, therefore, be involved in these conflicting results. In addition, it should be noted that the CFUs assays in the study of We have confirmed our earlier finding of tumour protection against CTX by WR 2721, being greater at 400mgkg-1 than at 200mgkg-l. We have also found protection against cis-P at 200 and 400mgkg-' of WR 2721. For the other cytotoxic agents there appeared to be a trend towards tumour protection, but with very small protection factors.
In conclusion, therefore, our data for differential chemoprotection by WR 2721 are distinctly less encouraging than the balance of other data in the literature. In most of our LD50 experiments, the protection factors were very small and in none of our white cell count experiments was significant protection seen. Only for cis-P in combination with 400mgkg-1 of WR 2721 was protection in excess of 1.5 seen for LD50. For this drug (and for CCNU) almost all deaths in the LD50/30 experiments occur 5-8 days after drug administration and are likely to be due to gastrointestinal damage. This LD50 factor may therefore be indicative of considerable variations in protection factors between various critical tissues. As the tumour protection factor for this combination is < 1.2 at cis-P doses in the LD50 region, then differential chemoprotection may occur and thus this combination may be worthy of further study. 
